https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
169
BREAST CANCER: GLOBAL BURDEN, RISK FACTORS,
ADVANCES IN DIAGNOSIS AND TREATMENT
Kamoljonova Go’zaloy Odiljon qizi
Abstract.
Breast cancer remains one of the most significant global health
challenges affecting women. With over 2.3 million new cases diagnosed in 2020,
it continues to pose a considerable burden on healthcare systems, especially in low-
and middle-income countries. This review explores the global burden of breast
cancer, its risk factors, and recent advancements in diagnostic and therapeutic
strategies. Emphasis is placed on the need for early detection and equitable access
to advanced treatments to improve survival outcomes worldwide.
Keywords
: Breast cancer, global burden, risk factors, diagnosis, treatment,
public health, molecular imaging, precision medicine
Introduction.
Breast cancer has long been recognized as one of the most
prevalent and deadly cancers affecting women worldwide. It continues to be a
major public health concern, with significant implications for patients, healthcare
systems, and societies at large. Over the past decades, considerable progress has
been made in understanding its etiology, improving early detection, and advancing
therapeutic options. The complexity of the disease, coupled with its varying
presentation and progression, has made it a focal point of intensive medical
research. Awareness campaigns, international collaborations, and patient advocacy
have all contributed to a greater global response, yet challenges remain in achieving
equitable care across different regions.
Breast cancer remains the most commonly diagnosed cancer among women
globally. According to the World Health Organization, more than 2.3 million new
cases were reported in 2020 alone. It accounts for approximately 11.7% of all
cancer cases and ranks as the fifth leading cause of cancer-related deaths
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
170
worldwide. Disparities in incidence and mortality rates have been observed across
regions, with higher survival rates in high-income countries due to earlier detection
and better access to treatment. In contrast, many low- and middle-income countries
continue to experience higher mortality rates, often due to late-stage diagnosis and
limited healthcare infrastructure.
Additionally, urbanization and lifestyle transitions in developing countries
have contributed to an increasing incidence rate. As life expectancy improves and
more women reach the age of risk, the burden is expected to rise. The
psychological, social, and economic consequences of breast cancer extend beyond
the individual, affecting families and communities as well.
A range of risk factors has been identified in the development of breast cancer.
These include non-modifiable factors such as age, gender, genetic mutations
(notably BRCA1 and BRCA2), and family history. Hormonal factors, such as early
menarche, late menopause, and hormone replacement therapy, have also been
associated with increased risk. In addition, modifiable lifestyle factors such as
obesity, physical inactivity, alcohol consumption, and exposure to ionizing
radiation have been shown to contribute to the risk of developing breast cancer.
Recent studies have also indicated the potential role of environmental
exposures, dietary patterns, and socioeconomic status in influencing breast cancer
risk. The interplay between genetic predisposition and lifestyle factors has gained
interest, particularly in developing personalized prevention strategies. Moreover,
reproductive history and breastfeeding practices have been identified as protective
or risk-enhancing depending on various socio-biological contexts.
Significant advances have been made in breast cancer diagnosis.
Mammography has remained the cornerstone of early detection, with digital
mammography offering improved accuracy. Ultrasound and magnetic resonance
imaging (MRI) have been used as supplementary tools, particularly in high-risk
populations. More recently, molecular imaging and genomic testing have emerged,
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
171
enabling more personalized risk assessment and early detection strategies. Liquid
biopsy technologies are currently being explored to detect circulating tumor DNA,
offering a minimally invasive diagnostic alternative.
In addition to imaging and molecular techniques, artificial intelligence (AI)
has begun to play a transformative role in diagnostic accuracy. AI-based tools have
demonstrated potential in interpreting mammograms with high precision, reducing
false positives and negatives. Diagnostic protocols are increasingly integrating risk
stratification models, allowing for tailored screening intervals and methods based
on individual profiles.
Treatment of breast cancer has seen substantial improvements over the years.
Surgery, including lumpectomy and mastectomy, remains a primary modality,
often combined with radiation therapy. Systemic therapies have evolved to include
hormonal therapy, chemotherapy, and targeted therapies such as HER2 inhibitors
and CDK4/6 inhibitors. Immunotherapy is also being explored, particularly for
triple-negative breast cancer. Advances in precision medicine have allowed
treatments to be tailored based on the molecular and genetic profile of the tumor,
improving outcomes and minimizing adverse effects.
Supportive care has also become a key component of treatment, addressing
the emotional, nutritional, and psychological needs of patients. Long-term
survivorship programs are now being integrated into oncology practices,
emphasizing quality of life, monitoring for recurrence, and managing chronic
effects of treatment. Furthermore, access to clinical trials and novel agents remains
essential to push the boundaries of current therapeutic approaches.
Conclusion.
While breast cancer continues to impose a significant global
burden, remarkable progress has been achieved in understanding its risk factors,
enhancing diagnostic capabilities, and improving therapeutic outcomes. Continued
research, investment in public health infrastructure, and expansion of screening
programs will be critical in managing its impact. Equitable access to early detection
https://scientific-jl.com/luch/
Часть
-46
_ Том
-5_
июнь
-2025
172
and personalized treatments must be prioritized, especially in underserved regions,
to ensure that all individuals have the opportunity for better outcomes and survival.
References
1.
World Health Organization. (2021). Breast cancer. Retrieved
https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2.
Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global Cancer
Statistics 2020: GLOBOCAN estimates of incidence and mortality
worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for
Clinicians, 71(3), 209
–
249.
3.
Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: A
review. JAMA, 321(3), 288
–
300.
4.
Younes, R. N., & Elias, S. (2021). Advances in breast cancer
diagnosis and treatment. The Lancet Oncology, 22(5), e186
–
e195.
5.
American Cancer Society. (2023). Breast Cancer: Early
detection,
diagnosis,
and
staging.
Retrieved
https://www.cancer.org/cancer/breast-cancer/screening-tests-and-
6.
Torre, L. A., Islami, F., Siegel, R. L., Ward, E. M., & Jemal, A.
(2017). Global cancer in women: Burden and trends. Cancer Epidemiology,
Biomarkers & Prevention, 26(4), 444
–
457.
7.
Harbeck, N., Penault-Llorca, F., Cortes, J., et al. (2019). Breast
cancer. Nature Reviews Disease Primers, 5(1), 66.
8.
McDonald, E. S., Clark, A. S., Tchou, J., Zhang, P., &
Freedman, G. M. (2016). Clinical diagnosis and management of breast
cancer. Journal of Nuclear Medicine, 57(Supplement 1), 9S
–
16S.
